Background-For the diagnosis of myocardial cell damage the measurement of the serum concentrations of myofibrillar antigens has several potential advantages over the assessment of traditional serological markers. These include the expression of myofibrillar antigens as cardiospecific isoforms and their high intracellular concentrations. Recently a sensitive and specific enzyme immunoassay for cardiac troponin T has been developed that shows little crossreactivity with skeletal isoforms. Objective To characterise myocardial cell damage after orthotopic heart transplantation, concentrations of circulating troponin T were measured prospectively in serial blood samples from 19 consecutive patients taken during the first three months after transplantation. Results-Mean (SD) serum concentrations of cardiac troponin T reached a maximum of 3-6 (1.8) ,ug/l at 7-1 (4.2) days after transplantation and remained higher than 0*5 4ugIl (twice the detection limit of the assay) in all patients for at least 43 days (mean (SD) 59 (20) (Br HeartJI 1993;69:395-398) For the diagnosis of myocardial cell damage the measurement of serum concentrations of myofibrillar proteins (such as actin, myosin, tropomyosin, and the troponin complex) has several potential advantages over the measurement of traditional serological markers. These include the expression of myofibrillar proteins as cardio-specific isoforms and their high intracellular concentrations.1 A sensitive and specific enzyme immunoassay has been developed for cardiac troponin T which shows little cross-reactivity with the skeletal troponin T isoforms."3 As shown in previous studies, circulating troponin T is not detectable in the absence of cardiac muscle damage; serum concentrations increase only when troponin T is released from damaged myocytes during severe ischaemia45 or myocardial infarction.6 These studies showed that the diagnostic efficiency of troponin T measurements was better than that of total creatine kinase (CK) or CK-MB to CK ratios.
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In the present study we attempted to evaluate myocardial cell damage after orthotopic heart transplantation by serial measurements of troponin T.
Patients and methods

PATIENTS
We studied 19 consecutive patients (mean (SD) age 52 (6) years, two women) who underwent orthotopic heart transplantation at the Department of Cardiac Surgery, University of Heidelberg, Germany, between November 1989 and March 1991. Blood samples (4 ml) were obtained routinely in the first three months after surgery: every 1-2 days during the first two postoperative weeks and every 2-7 days thereafter.
IMMUNOSUPPRESSIVE REGIMEN
All patients were treated with a standard regimen of cyclosporin, corticosteroids, and azathioprine. All patients were given antithymocyte globulin (ATG) after operation until therapeutic concentrations of cyclosporin were reached (mean 6 days). During the study period the target concentration of cyclosporin in whole blood was 250-400 ,ug/l as assessed by radioimmunoassay with a monoclonal antibody. Administration of azathioprine was stopped when there were fewer than 4-0/nl blood leucocytes. Acute rejection episodes, diagnosed by endomyocardial biopsy, were initially treated with intravenous methylprednisolone (1 g daily for three days). One of the study patients received monoclonal Zimmermann, Baki, Dengler, Ring, Remppis, Lange, Hagl, Kubler, Katus anti-T3-receptor antibodies (OKT3) for 10 days because of ongoing acute rejection despite two courses of intravenous methylprednisolone and one course of ATG.
TROPONIN T SERUM CONCENTRATIONS
Concentrations of circulating troponin T were measured by a one-step enzyme immunoassay with two specific monoclonal antibodies and streptavidin coated tubes as the solid phase.25 The capture antibody was labelled with biotin, the second antibody was conjugated to horseradish peroxidase. We performed the assays within 90 minutes at room temperature using the Enzymun-Test system (Boehringer Mannheim GmbH, Germany) (range 0 20-15,ug/1). Cumulative troponin T release was defined as the area under the troponin T serum concentration curve within the time interval of the study period (that is, 3 months after transplantation) and was calculated by the trapezoidal rule.
Continuous data are given as mean and SD.
Results Figure 1 shows a typical time course for serum troponin T concentrations after heart transplantation. The troponin T concentration was 3 0,ug/l on the first postoperative day, increased to a maximum of 3-6 jug/l on day 5, and then decreased exponentially. The half time was approximately 10 days.
All 19 patients showed similar time courses of postoperative troponin T serum concentraAcute moderate rejections tion. Mean serum troponin T concentrations (fig 2) reached a maximum of 3-6 (1.8) ,ug/l at 7-1 (4.2) days after transplantation and remained higher than 0-5 ,ug/l (that is, twice the detection limit of the assay) in all patients for at least 29 days (mean (SD) 59 1 (20.0) days). In most patients the pattern of troponin T release was unchanged during moderate and severe acute rejection episodes ( fig  3) . But as fig 1 shows, in some patients the rejection episode was preceded by a slight transient increase in troponin T release.
Cumulative troponin T release in individual patients ranged from 27 to 150 ,ug x days/l (mean, 71 (30) jug x days/l). Cumulative troponin T release was not related to total ischaemic time before transplantation (fig 4) , to the patient's renal or hepatic function, to preoperative cardiac diseases, or to matching for the major histocompatibility complex (MHC). Cumulative troponin T release was also similar in patients without acute rejection episodes during the first postoperative year (69 (18) ug x days/l, n = 4) and in patients with one episode (76 (4) ,ig x days/l, n = 4), two (80 (18) ,ug x days/l n = 3), and more than two episodes of acute rejection (67 (31) jug x days/l, n = 8).
Cardiac Days Figure 5 Time course of cardiac troponin T (cTnT) serum concentrations after minor Q wave myocardial infarction,6 heart transplantation (current data), and coronary artery bypass surgery7 during the first 30 postoperative days. tion, troponin T appears in the cir within 3-5 hours after onset of chest p troponin T concentrations remain ii for at least six days but no longer days. 4 Smaller amounts of circulat ponin T were also detectable after ( artery bypass grafting or valve repla troponin T release and the length of t troponin T appeared in the circulati significantly related to the aortic cro; time during operation. 6 Our results in patients with heai plants differ from these earlier studie eral ways. First, troponin T release patients was not related to total is time before transplantation (fig 4) . S the time course of troponin T release ferent: concentrations of circulating i T increased during the first 5-10 d were still detectable for a mean of after surgery ( fig 5) . Furthermore, td considerable variation in cumulative T release among the patients 27-150 jug x days/l and release M associated with any of the clinical studied.
These observations are consiste after heart transplantation.89 These studies iime that showed considerable myocardial antimyosin ion were uptake soon after transplantation with gradss clamp ual reduction during the subsequent months.
In some patients, however, cardiac uptake of rt transantimyosin antibody continued for more than s in sev-one year after heart transplantation and rejecin our tion related complications were more com-,chaemic mon in such patients. In our study, however, ,econdly, serum troponin T concentrations decreased was dif-below the detection limit of the assay within troponin three months of transplantation in all patients lays and (fig 2) . The reason for the discrepancy 59 days between labelled antimyosin and troponin T, here was tion episodes after transplantation. These findings may be explained by prolonged leakage of cytosolic troponin T (from viable myocytes) as well as prolonged disintegration of myofibres (from irreversibly damaged myocytes) during the first months after heart transplantation.
